These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

403 related items for PubMed ID: 19635445

  • 1. Fluconazole and amphotericin B susceptibility testing of Cryptococcus neoformans: results of minimal inhibitory concentrations against 265 isolates from HIV-positive patients before and after two or more months of antifungal therapy.
    Arechavala AI, Ochiuzzi ME, Borgnia MD, Santiso GM.
    Rev Iberoam Micol; 2009 Sep 30; 26(3):194-7. PubMed ID: 19635445
    [Abstract] [Full Text] [Related]

  • 2. Antifungal susceptibilities of Cryptococcus neoformans cerebrospinal fluid isolates and clinical outcomes of cryptococcal meningitis in HIV-infected patients with/without fluconazole prophylaxis.
    Manosuthi W, Sungkanuparph S, Thongyen S, Chumpathat N, Eampokalap B, Thawornwan U, Foongladda S.
    J Med Assoc Thai; 2006 Jun 30; 89(6):795-802. PubMed ID: 16850679
    [Abstract] [Full Text] [Related]

  • 3. Correlation of Etest and Neo-Sensitabs diffusion assays on Mueller-Hinton-methylene blue agar with broth microdilution reference method (CLSI-M27-A2) for testing susceptibilities of Cryptococcus neoformans to amphotericin B and fluconazole.
    Ochiuzzi ME, Santiso GM, Arechavala AI.
    Med Mycol; 2010 Sep 30; 48(6):893-6. PubMed ID: 20370370
    [Abstract] [Full Text] [Related]

  • 4. In vitro antifungal activities of amphotericin B, 5-fluorocytosine, fluconazole and itraconazole against Cryptococcus neoformans isolated from cerebrospinal fluid and blood from patients in Serbia.
    Trpković A, Pekmezović M, Barać A, Crnčević Radović L, Arsić Arsenijević V.
    J Mycol Med; 2012 Sep 30; 22(3):243-8. PubMed ID: 23518082
    [Abstract] [Full Text] [Related]

  • 5. Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates in the United States: 1992 to 1994 and 1996 to 1998.
    Brandt ME, Pfaller MA, Hajjeh RA, Hamill RJ, Pappas PG, Reingold AL, Rimland D, Warnock DW, Cryptococcal Disease Active Surveillance Group.
    Antimicrob Agents Chemother; 2001 Nov 30; 45(11):3065-9. PubMed ID: 11600357
    [Abstract] [Full Text] [Related]

  • 6. Susceptibility of clinical isolates of Cryptococcus neoformans to amphotericin B using time-kill methodology.
    Pappalardo MC, Szeszs MW, Martins MA, Baceti LB, Bonfietti LX, Purisco SU, Baez AA, Melhem MS.
    Diagn Microbiol Infect Dis; 2009 Jun 30; 64(2):146-51. PubMed ID: 19345042
    [Abstract] [Full Text] [Related]

  • 7. Efficacy of amphotericin B in combination with flucytosine against flucytosine-susceptible or flucytosine-resistant isolates of Cryptococcus neoformans during disseminated murine cryptococcosis.
    Schwarz P, Dromer F, Lortholary O, Dannaoui E.
    Antimicrob Agents Chemother; 2006 Jan 30; 50(1):113-20. PubMed ID: 16377675
    [Abstract] [Full Text] [Related]

  • 8. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America.
    Saag MS, Graybill RJ, Larsen RA, Pappas PG, Perfect JR, Powderly WG, Sobel JD, Dismukes WE.
    Clin Infect Dis; 2000 Apr 30; 30(4):710-8. PubMed ID: 10770733
    [Abstract] [Full Text] [Related]

  • 9. Antifungal susceptibility of Cryptococcus neoformans to amphotericin B and fluconazole.
    Khyriem AB, Sujatha S, Parija SC.
    Indian J Pathol Microbiol; 2006 Apr 30; 49(2):307-8. PubMed ID: 16933750
    [Abstract] [Full Text] [Related]

  • 10. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003.
    Hsueh PR, Lau YJ, Chuang YC, Wan JH, Huang WK, Shyr JM, Yan JJ, Yu KW, Wu JJ, Ko WC, Yang YC, Liu YC, Teng LJ, Liu CY, Luh KT.
    Antimicrob Agents Chemother; 2005 Feb 30; 49(2):512-7. PubMed ID: 15673726
    [Abstract] [Full Text] [Related]

  • 11. In vitro susceptibility of Cryptococcus neoformans clinical isolates from Egypt to seven antifungal drugs.
    Abdel-Salam HA.
    Mycoses; 2005 Sep 30; 48(5):327-32. PubMed ID: 16115103
    [Abstract] [Full Text] [Related]

  • 12. Current scenario of cryptococcosis and antifungal susceptibility pattern in India: a cause for reappraisal.
    Capoor MR, Mandal P, Deb M, Aggarwal P, Banerjee U.
    Mycoses; 2008 May 30; 51(3):258-65. PubMed ID: 18399907
    [Abstract] [Full Text] [Related]

  • 13. In vitro susceptibilities of Malaysian clinical isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii to five antifungal drugs.
    Tay ST, Tanty Haryanty T, Ng KP, Rohani MY, Hamimah H.
    Mycoses; 2006 Jul 30; 49(4):324-30. PubMed ID: 16784448
    [Abstract] [Full Text] [Related]

  • 14. Serotypes of clinical cerebrospinal fluid Cryptococcus neoformans isolates from southern Taiwan and their in vitro susceptibilities to amphotericin B, fluconazole, and voriconazole.
    Chang WN, Huang CR, Lei CB, Lee PY, Chien CC, Chang HW, Chang CS, Lu CH.
    Jpn J Infect Dis; 2004 Jun 30; 57(3):113-5. PubMed ID: 15218221
    [Abstract] [Full Text] [Related]

  • 15. Increasing in vitro resistance to fluconazole in Cryptococcus neoformans Cambodian isolates: April 2000 to March 2002.
    Sar B, Monchy D, Vann M, Keo C, Sarthou JL, Buisson Y.
    J Antimicrob Chemother; 2004 Aug 30; 54(2):563-5. PubMed ID: 15254027
    [Abstract] [Full Text] [Related]

  • 16. Response to therapy in patients with cryptococcosis and AIDS: Association with in vitro susceptibility to fluconazole.
    Agudelo CA, Muñoz C, Ramírez A, Tobón AM, de Bedout Bact C, Cano LE, Restrepo A.
    Rev Iberoam Micol; 2015 Aug 30; 32(4):214-20. PubMed ID: 25637338
    [Abstract] [Full Text] [Related]

  • 17. Results obtained with various antifungal susceptibility testing methods do not predict early clinical outcome in patients with cryptococcosis.
    Dannaoui E, Abdul M, Arpin M, Michel-Nguyen A, Piens MA, Favel A, Lortholary O, Dromer F, French Cryptococcosis Study Group.
    Antimicrob Agents Chemother; 2006 Jul 30; 50(7):2464-70. PubMed ID: 16801427
    [Abstract] [Full Text] [Related]

  • 18. Rates of antifungal resistance among Spanish clinical isolates of Cryptococcus neoformans var. neoformans.
    Perkins A, Gomez-Lopez A, Mellado E, Rodriguez-Tudela JL, Cuenca-Estrella M.
    J Antimicrob Chemother; 2005 Dec 30; 56(6):1144-7. PubMed ID: 16282208
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of antifungal combination against Cryptococcus spp.
    Reichert-Lima F, Busso-Lopes AF, Lyra L, Peron IH, Taguchi H, Mikami Y, Kamei K, Moretti ML, Schreiber AZ.
    Mycoses; 2016 Sep 30; 59(9):585-93. PubMed ID: 27135278
    [Abstract] [Full Text] [Related]

  • 20. Susceptibility profile and epidemiological cut-off values of Cryptococcus neoformans species complex from Argentina.
    Córdoba S, Isla MG, Szusz W, Vivot W, Altamirano R, Davel G.
    Mycoses; 2016 Jun 30; 59(6):351-6. PubMed ID: 26865081
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.